Bull case
Gain Therapeutics is attractive fundamentally because its lead candidate GT-02287 has already shown target engagement, favorable safety and tolerability, and a compelling biomarker response, including an average 81% reduction in CSF glucosylsphingosine after 90 days in patients with elevated baseline levels. The company also has an FDA-authorized Phase 2 path for Parkinson’s disease with or without a GBA1 mutation, and the latest data suggest a multi-biomarker signal—lower DDC, improved or stable MDS-UPDRS scores, and anecdotal gains in smell, gait, and sleep—that supports a disease-modifying thesis rather than purely symptomatic benefit. While Phase 2 initiation has shifted to 1Q27 from 3Q26 and the trial design remains in flux, the extensive preclinical package, ongoing extension data, and platform-driven ability to rapidly identify allosteric modulators strengthen the long-term opportunity.